Dr. Kevin Scanlon’s career spans roles in academic medicine, senior management in the pharmaceutical industry and biotech companies, as well as an individual investor. Currently, he is an investment advisor to Sky Ventures in Boston, MA and a Professor of Practice at Northeastern University.
He served as the Chairman of Pasadena Angels Investment Group (Pasadena, CA), with ~100 investors that funded over 50 companies in two years. He has been CEO of four biotechnology companies, including Melanoma Diagnostics, which was sold to Myriad Genetics. At Schering AG (Berlin, Germany), he was responsible for the genomic and cancer programs in the US, Europe and Asia.
Dr. Scanlon’s notable academic achievements include: Leukemia Society Scholar, Paul Martini Medical Research Prize (Cancer, Germany), Co-Founder of the Nature Journal “Cancer Gene Therapy”, President of the International Society of Cell and Gene Therapy, co-authoring 135 peer-reviewed scientific articles and nine medical books. Dr. Scanlon also holds seven issued US Patents.